SiOxMed has partnered with Gifthealth to offer its steroid-free prescription skin cream to patients with atopic dermatitis and allergic contact dermatitis.

SiOxMed has partnered with US pharmacy services provider Gifthealth to make its prescription-only SiOxC Cream available directly to patients with atopic dermatitis and allergic contact dermatitis.

The collaboration will allow clinicians to prescribe the non-steroidal topical skin emulsion through their electronic health record (EHR) systems, with Gifthealth managing prescription verification, payment and home delivery.

SiOxC is indicated for the management of pruritus (itching) and skin dryness associated with the two inflammatory skin conditions. The product received FDA 510(k) clearance in March 2025 and is designed to maintain a moist skin environment.

The partnership is intended to simplify access to the cream by removing the need for patients to visit a pharmacy to collect their prescription.

Patients can access cream for $40

At launch, patients will be able to obtain a one-ounce supply for a cash price starting at $40, regardless of their insurance coverage.

Once Gifthealth receives a prescription, it will send the patient a text message within 45 to 60 seconds, providing the price, delivery options and a link to complete the purchase, subject to appropriate consent.

Gifthealth will then arrange delivery to the patient’s home.

The companies said the arrangement is designed to connect prescribing clinicians with patients through a single process, while leaving existing prescriber workflows unchanged.

Adam Jorgensen, chief technology and operations officer at SiOxMed, said: “We developed SiOxC Cream to provide clinicians with a steroid-free prescription option for these symptoms, and our partnership with Gifthealth helps ensure that once a clinician chooses SiOxC, getting it into the patient’s hands is simple, transparent, and convenient.”

Insurance support planned for 2027

The initial programme is based on a cash-pay model, but the companies plan to extend the service in early 2027 to include prior authorisation and copay support for patients with commercial health insurance.

This would allow eligible patients to access SiOxC through the same prescription-to-home-delivery process, with Gifthealth handling the additional insurance-related requirements.

Jeremy Richardson, chief commercial officer at Gifthealth, said: “Our role is to make access to that option straightforward and transparent.”

He added that the company would look to broaden access through its pharmacy platform over time.

A prescription skin emulsion for dermatitis

SiOxMed develops silica-based biomaterials for applications in wound care, dermatology, trauma and surgical medicine.

SiOxC is a prescription-only topical skin emulsion containing amorphous silica fibres. The formulation is intended to support a moist environment on the skin. The fibres are designed to absorb and retain moisture rather than being absorbed into the skin.

Its FDA-cleared indications cover the management of itching and dryness associated with atopic dermatitis and allergic contact dermatitis. It is not intended for use on breached or compromised skin or open sores.

The Gifthealth partnership represents a commercial expansion of access to an existing product rather than a new clinical or regulatory milestone.

Prescribers can find further information about SiOxC through SiOxMed’s product information.